Javascript must be enabled to continue!
Biodistribution and Targeted Antitumor Effects of Trastuzumab-Modified Gold Nanorods in Mice with Gastric Cancer
View through CrossRef
Background and Objectives:
Targeted drug is often engulfed and cleared by the reticuloendothelial
system in vivo, resulting in reduced treatment efficacy. This study aimed to explore the biodistribution
and HER-2-targeted antitumor effects of trastuzumab-modified gold nanorods (Tra-AuNRs) in
a gastric cancer animal model.
Methods:
Gold nanorods were synthesized using a seed-mediated growth method, and then subjected to
trastuzumab-targeted modification. Elemental analysis, Fourier transform infrared spectroscopy, and Xray
photoelectron spectroscopy were performed; UV-visible absorption peak, photothermal effects,
morphology, and size distribution of Tra-AuNRs were characterized. The targeted killing effect of Tra-
AuNRs on gastric cancer cells was assessed in vitro. Tra-AuNRs were injected intravenously and intratumorally
into gastric cancer-bearing nude mice in vivo and their distribution was detected. Tumor
growth inhibition rate and tumor apoptosis-related protein expression were compared between groups.
Results:
Tra-AuNRs presented a relatively uniform morphology with an average particle size of 59.9
nm and a longitudinal plasmon resonance absorption peak of 790 nm. The targeted killing rate of gastric
cancer cells in vitro by Tra-AuNRs was 87.9%. After intravenous injection, Tra-AuNRs were mainly
distributed in the liver, tumor, spleen, and lungs. Comparatively, Tra-AuNRs were mainly distributed
in the tumor when intratumorally injected, with a tumor concentration of 6.42 μg/g after 24 h. The tumor
growth inhibition rate reached 78.3% in the intratumoral injection group, with significantly higher
BAX, BAD, and CASPASE-3 expression than that in the intravenous injection group.
Conclusion:
The findings suggest that Tra-AuNRs can be used for HER-2-positive gastric cancer
treatment. Intratumoral injection of Tra-AuNRs significantly increased the local tumor drug concentration
and improved the molecular targeted antitumor growth effect in gastric cancer-bearing nude mice.
Bentham Science Publishers Ltd.
Title: Biodistribution and Targeted Antitumor Effects of Trastuzumab-Modified
Gold Nanorods in Mice with Gastric Cancer
Description:
Background and Objectives:
Targeted drug is often engulfed and cleared by the reticuloendothelial
system in vivo, resulting in reduced treatment efficacy.
This study aimed to explore the biodistribution
and HER-2-targeted antitumor effects of trastuzumab-modified gold nanorods (Tra-AuNRs) in
a gastric cancer animal model.
Methods:
Gold nanorods were synthesized using a seed-mediated growth method, and then subjected to
trastuzumab-targeted modification.
Elemental analysis, Fourier transform infrared spectroscopy, and Xray
photoelectron spectroscopy were performed; UV-visible absorption peak, photothermal effects,
morphology, and size distribution of Tra-AuNRs were characterized.
The targeted killing effect of Tra-
AuNRs on gastric cancer cells was assessed in vitro.
Tra-AuNRs were injected intravenously and intratumorally
into gastric cancer-bearing nude mice in vivo and their distribution was detected.
Tumor
growth inhibition rate and tumor apoptosis-related protein expression were compared between groups.
Results:
Tra-AuNRs presented a relatively uniform morphology with an average particle size of 59.
9
nm and a longitudinal plasmon resonance absorption peak of 790 nm.
The targeted killing rate of gastric
cancer cells in vitro by Tra-AuNRs was 87.
9%.
After intravenous injection, Tra-AuNRs were mainly
distributed in the liver, tumor, spleen, and lungs.
Comparatively, Tra-AuNRs were mainly distributed
in the tumor when intratumorally injected, with a tumor concentration of 6.
42 μg/g after 24 h.
The tumor
growth inhibition rate reached 78.
3% in the intratumoral injection group, with significantly higher
BAX, BAD, and CASPASE-3 expression than that in the intravenous injection group.
Conclusion:
The findings suggest that Tra-AuNRs can be used for HER-2-positive gastric cancer
treatment.
Intratumoral injection of Tra-AuNRs significantly increased the local tumor drug concentration
and improved the molecular targeted antitumor growth effect in gastric cancer-bearing nude mice.
Related Results
Abstract 1737: Overcoming trastuzumab resistance with the irreversible Pan-HER inhibitor neratinib
Abstract 1737: Overcoming trastuzumab resistance with the irreversible Pan-HER inhibitor neratinib
Abstract
Overexpression of HER2 is seen in 15-20% of breast cancer and is a predictor of poor prognosis. Trastuzumab, a monoclonal antibody to the ECD of the HER2 re...
Abstract PO5-07-11: Use of 64Cu-DOTA trastuzumab -PET to predict response to trastuzumab-deruxtecan (TDXd) in patients with metastatic disease to the brain: Study in Progress
Abstract PO5-07-11: Use of 64Cu-DOTA trastuzumab -PET to predict response to trastuzumab-deruxtecan (TDXd) in patients with metastatic disease to the brain: Study in Progress
Abstract
Background: We have utilized 64Cu-DOTA trastuzumab-PET imaging in patients with advanced breast cancer. In our experience, uptake on 64Cu-DOTA trastuzumab-P...
Abstract 1821: HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer
Abstract 1821: HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer
Abstract
Background: Trastuzumab is a standard therapy for HER2-positive breast cancer patients. Majority of the patients treated with trastuzumab in metastatic dise...
Abstract 2130A: Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models
Abstract 2130A: Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models
Abstract
Introduction: The major clinical problem for HER2 breast cancer target therapies is the acquisition of resistance. Trastuzumab has been used for the treatme...
Abstract 1530: Trastuzumab treatment induces ADAM17 and HER ligands in vivo
Abstract 1530: Trastuzumab treatment induces ADAM17 and HER ligands in vivo
Abstract
Anti-HER2 monoclonal antibody trastuzumab is used as treatment in patients with HER2 positive breast cancer. However, resistance inevitably occurs for all r...
Data from Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity
Data from Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity
<div>Abstract<p><b>Purpose:</b> Malignant rhabdoid tumor (MRT) is an early childhood cancer with poor prognosis. Trastuzumab, a humanized monoclonal antibod...
Data from Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity
Data from Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity
<div>Abstract<p><b>Purpose:</b> Malignant rhabdoid tumor (MRT) is an early childhood cancer with poor prognosis. Trastuzumab, a humanized monoclonal antibod...
Abstract 5120: NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic human NSCLC in a humanized mouse model
Abstract 5120: NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic human NSCLC in a humanized mouse model
Abstract
NPRL2/TUSC4 is a potent tumor suppressor gene whose expression is reduced in many cancers including NSCLC. Restoration of NPRL2 expression in cancer cells i...

